MENU
+Compare
PGEN
Stock ticker: NASDAQ
AS OF
Nov 26, 04:59 PM (EDT)
Price
$3.75
Change
+$0.08 (+2.18%)
Capitalization
1.32B

PGEN Precigen Forecast, Technical & Fundamental Analysis

Precigen Inc is a biotechnology company that develops synthetic biology solutions... Show more

PGEN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for PGEN with price predictions
Nov 25, 2025

PGEN in upward trend: 10-day moving average broke above 50-day moving average on October 24, 2025

The 10-day moving average for PGEN crossed bullishly above the 50-day moving average on October 24, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where PGEN advanced for three days, in of 232 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 157 cases where PGEN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for PGEN moved out of overbought territory on November 19, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on November 20, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on PGEN as a result. In of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for PGEN turned negative on November 20, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .

PGEN moved below its 50-day moving average on November 24, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PGEN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

PGEN broke above its upper Bollinger Band on November 14, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (31.646) is normal, around the industry mean (27.690). P/E Ratio (0.000) is within average values for comparable stocks, (51.985). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.895). Dividend Yield (0.000) settles around the average of (0.048) among similar stocks. P/S Ratio (175.439) is also within normal values, averaging (322.277).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

View a ticker or compare two or three
PGEN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

PGEN is expected to report earnings to fall 94.34% to -5 cents per share on March 09

Precigen PGEN Stock Earnings Reports
Q4'25
Est.
$-0.06
Q3'25
Missed
by $0.97
Q2'25
Missed
by $0.01
Q1'25
Missed
by $0.10
Q4'24
Missed
by $0.01
The last earnings report on November 13 showed earnings per share of -105 cents, missing the estimate of -9 cents. With 3.30M shares outstanding, the current market capitalization sits at 1.32B.
A.I. Advisor
published General Information

General Information

a biotechnology company, which engages in the research and development of synthetic biology technologies.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
20374 Seneca Meadows Parkway
Phone
+1 301 556-9900
Employees
202
Web
http://www.precigen.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SLCGX34.12N/A
N/A
Saratoga Large Capitalization Growth I
KTCIX56.10N/A
N/A
DWS Science and Technology Inst
STEYX17.06N/A
N/A
AB International Strat Eqs Adv
SUVQX13.85N/A
N/A
PGIM Quant Solutions Large-Cap Val R6
USRAX34.27N/A
N/A
Horizon Multi-Factor U.S. Equity Inv

PGEN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, PGEN has been loosely correlated with ARRY. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if PGEN jumps, then ARRY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PGEN
1D Price
Change %
PGEN100%
-3.93%
ARRY - PGEN
39%
Loosely correlated
+5.96%
VCYT - PGEN
39%
Loosely correlated
+5.74%
AXON - PGEN
38%
Loosely correlated
+0.82%
MRNA - PGEN
38%
Loosely correlated
+2.48%
CLDX - PGEN
37%
Loosely correlated
+0.46%
More